Seattle Genetics has built its success mainly on brentuximab vedotin, and it doesn't appear to be slowing down there.
Innovations are needed if it's going to keep growing.
Cascadian Therapeutics' answer to HER2-positive breast cancer might be the shot in the arm the company needs to reach a new level.
Note: This article was presented early to subscribers of the Total Pharma Tracker, offering a quicker take on this news. Consider subscribing today to support me and to get updates sooner!
The news for